Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,689 recruiting studies in this area right now.
By phase
- Not applicable9,836
- Phase 24,475
- Phase 12,738
- Phase 1/Phase 21,689
- Phase 31,406
- Phase 2/Phase 3282
- Phase 4263
Top conditions
- Breast Cancer1,231
- Prostate Cancer659
- Cancer658
- Colorectal Cancer495
- Lung Cancer430
- Ovarian Cancer338
- Multiple Myeloma330
- Gastric Cancer300
- Pancreatic Cancer298
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma286
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer205
- Advanced Solid Tumors196
- Esophageal Cancer195
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University312
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- National Cancer Institute (NCI)288
- Mayo Clinic236
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto126
Where studies are running
- California1,427
- Texas642
- Arizona513
- Florida443
- Alabama421
- New York412
- Massachusetts340
- Maryland328
- New Jersey268
- Pennsylvania240
Recruiting studies20,689 total
- NCT05856643RecruitingEarly Phase 1
Study drug for ovarian cancer after prior treatment failure
This early-phase study tests SZ011 in people with ovarian epithelial cancer that has come back or did not respond to standard first treatment. You may qualify if your tumor shows a specific marker (mesothelin) and your health tests are strong enough to safely receive the study drug.
Shantou, GuangdongAges 18–80 - NCT05856981RecruitingPhase 1
Testing ADU-1805 for advanced solid tumors safety
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Detroit, MichiganAges 18 years+ - NCT05857800Recruiting
Studying how lung tumor treatment affects the tumor environment
This trial studies how “before-surgery” (neoadjuvant) lung cancer treatments change the tumor environment by monitoring patients during care. It may help doctors better choose therapies and predict who benefits from treatment.
ShanghaiAges 18 years+ - NCT05857631Recruiting
After-surgery radiation schedule for cervical or uterine cancers
This trial studies a shorter, focused radiation schedule given after surgery for certain higher-risk cervical or endometrial (uterine) cancers. It may help reduce cancer recurrence while checking side effects in the bladder and bowel area.
Navi Mumbai, MaharahstraAges 18–80 - NCT05858307Recruiting
Testing AMH blood levels for PCOS and POI patients
This study looks at how a blood test called AMH (anti-Müllerian hormone) is used in people being seen for PCOS or POI (early ovarian failure). The goal is to understand whether AMH measurements are useful for care in clinics and fertility treatment settings.
Hong KongAges 10–44 - NCT05857995Recruiting
Personalized survivorship care program for rural lung cancer survivors
This study tests a personalized care program to help people who have had lung cancer manage life after treatment. It focuses on survivors living in rural areas, aiming to improve follow-up care and support.
Lexington, KentuckyAges 18 years+ - NCT05858398Recruiting
How body composition affects chemotherapy results in breast cancer
This study looks at whether body fat and muscle (body composition) change how well certain chemotherapy works after surgery for early breast cancer. You may be considered if you are planned to receive docetaxel as adjuvant (after-surgery) chemotherapy and have recent CT scan images.
RouenAges 18 years+ - NCT05858424Recruiting
Day hospital program to improve young cancer survivors’ well-being
This study tests a structured “end-of-treatment” day hospital program to improve quality of life for adolescents and young adults after cancer treatment. You may be offered follow-up and supportive care soon after finishing treatment to help you feel better physically and emotionally.
LyonAges 15–25 - NCT05858814RecruitingPhase 1/Phase 2
Cell therapy to help prevent AML relapse after transplant
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
Hefei, AnhuiAges 18–70 - NCT05860361Recruiting
Registry to collect proton therapy data for cancer patients
This study collects high-quality information about people who are planning to receive proton therapy for cancer or other tumors. It does not change your treatment; it helps researchers improve proton therapy for future patients.
MilanAges 18 years+ - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT05859750RecruitingPhase 2
AK104 plus chemotherapy for advanced pancreatic cancer
This trial tests AK104 (an antibody medicine) given with standard chemotherapy as the first treatment for advanced pancreatic ductal cancer. It aims to see whether this combination works better and is safe for people with cancer that has spread or is advanced.
Beijing, Beijing MunicipalityAges 18–75 - NCT05859659Recruiting
Hope HOPE study for glioma using pathology and MRI
This study looks at glioma (a type of brain tumor) and uses brain tissue testing, MRI scans, and related measurements to better understand the disease. You may benefit by being closely assessed with MRI and study follow-up, though it’s not necessarily testing a new medicine based on the listed criteria.
Beijing, Beijing MunicipalityAges 18–90 - NCT05860465RecruitingPhase 2/Phase 3
Tested blood cancer medicine with hormone therapy for breast cancer
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
Guangzhou, GuangdongAges 18–75 - NCT05861245Recruiting
Proton radiation in 5 or 25 treatments for skull-base tumors
This trial tests a radiation plan using protons given in either 5 or 25 sessions for chordoma or chondrosarcoma at the skull base. The goal is to shrink or control the tumor while protecting nearby critical nerves and brain structures.
Madrid, MadridAges 18 years+ - NCT05861271RecruitingPhase 2
Adjuvant pyrotinib plus capecitabine for tiny HER2 breast cancer
This trial studies whether adding pyrotinib and capecitabine after surgery can lower the risk of cancer coming back in people with very small, lymph-node–negative, HER2-positive breast cancer. It’s for patients who fit specific tumor size and HER2 test results and who can safely take chemotherapy-like medicines and stay on contraception during treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05861505RecruitingPhase 3
Treatment for new liver spread from colon cancer recurrence
This Phase 3 trial studies a treatment approach for people whose colorectal cancer has come back in the liver within 12 months and can be treated with local procedures. It aims to see whether the study treatment can improve outcomes compared with standard care for people with a limited number of liver tumors.
AmsterdamAges 18 years+ - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05862012RecruitingPhase 1
Test drug ISB 2001 in multiple myeloma patients who relapsed
This Phase 1 study tests ISB 2001, a new investigational treatment, in people with multiple myeloma that has come back or not responded to prior treatment. It mainly focuses on safety and whether the drug can be given effectively.
Palo Alto, CaliforniaAges 18 years+ - NCT05862740Recruiting
Surgery study for advanced ovarian cancer after chemotherapy
This study looks at how well a minimally invasive surgery (laparoscopic debulking) can remove tumor in people with advanced epithelial ovarian cancer. It may help doctors compare whether this approach is safe and effective for patients who need either upfront surgery or surgery after chemotherapy.
Padova, Padova, VenetoAges 18 years+ - NCT05862259Recruiting
Immunotherapy as first treatment for advanced stage IV cancers
This study looks at whether immune checkpoint inhibitors given as the first treatment work well and are safe for people with advanced (stage IV) solid tumors. You might qualify if you can take study treatment reliably and your cancer type and health match the study rules.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05862168RecruitingPhase 2
Tislelizumab with chemotherapy before surgery for oral cancer
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
HangzhouAges 18–75 - NCT05862272RecruitingPhase 3
Testing long-term bone density support in fibroids or endometriosis
This study tests how well a long-term treatment using a relugolix combination tablet helps protect bone density in women who have uterine fibroids or endometriosis. It may help people who are at risk of bone thinning while receiving hormone-related symptom treatment.
Mobile, AlabamaAges 18–50 - NCT05862337RecruitingPhase 3
New immune plus anti-cancer pills to prevent liver cancer returning
This Phase 3 trial studies anlotinib capsules plus penpulimab (an immune therapy) to help prevent hepatocellular carcinoma from coming back after it has been fully removed or fully destroyed. It may help high-risk patients lower the chance of recurrence and improve survival.
Bengbu, AnhuiAges 18–75
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,689 recruiting oncology studies from the U.S. registry right now, out of 31,955 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.